written on 08.05.2014

Can payers get to 'rational' hep C drug prices without a price war?


Payers worried about hepatitis C drug prices have been counting on impending price competition to save them money. The idea is that, once Merck, AbbVie and Bristol-Myers Squibb have treatments on the market, Gilead Sciences will have to back off its $84,000-per-treatment-course sticker price. The reality could be a little better–and a little worse–than that.